Christopher Cabell - 05 Jan 2026 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role: President & Head of R&D
Signature: /s/ Mark Iwicki, attorney-in-fact
Issuer symbol: IKT
Transactions as of: 05 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 07 Jan 2026, 16:21:52 UTC
Previous filing: 02 Jul 2025
Next filing: 24 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cabell Christopher	President & Head of R&D	1000 N. WEST STREET, SUITE 1200, WILMINGTON	/s/ Mark Iwicki, attorney-in-fact	07 Jan 2026	0001814928

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IKT	Stock Option (Right to Buy)	Award	$0	+900,117		$0.000000	900,117	05 Jan 2026	Common Stock	900,117	$2.01	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.